Severe Acute Respiratory Syndrome–Coronavirus-2 Infection and Patients With Lung Cancer: The Potential Role of Interleukin-17 Target Therapy

• Published in: Journal of thoracic oncology Vol. 15; no. 7; pp. e101 - e103
• Main Author: Cafarotti, Stefano
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.07.2020; Copyright by the International Association for the Study of Lung Cancer; International Association for the Study of Lung Cancer. Published by Elsevier Inc
• Subjects: Betacoronavirus - drug effects; Betacoronavirus - physiology; Chemokines, CXC - metabolism; Coronavirus Infections - drug therapy; Coronavirus Infections - immunology; COVID-19; Drug Discovery; Humans; IL-17 target therapy; Inflammation - immunology; Interleukin-17 - antagonists & inhibitors; Interleukin-17 - immunology; Letter to the Editor; Lung cancer; Lung Neoplasms - drug therapy; Lung Neoplasms - immunology; Molecular Targeted Therapy - methods; Monoclonal antibody; Pandemics; Pneumonia, Viral - drug therapy; Pneumonia, Viral - immunology; Respiratory Distress Syndrome - drug therapy; Respiratory Distress Syndrome - immunology; SARS-CoV-2; Th17 Cells - immunology; Up-Regulation - drug effects; COVID-19; Monoclonal antibody; Lung cancer; IL-17 target therapy
• ISSN: 1556-0864; 1556-1380; 1556-1380
• DOI: 10.1016/j.jtho.2020.04.015

The coronavirus disease 2019 outbreak is evolving rapidly worldwide. The lungs are the target of the primary infection and patients with lung cancer seem to have a poor prognosis. To our knowledge, this is the first reported investigation of a possible role of interleukin-17 target therapy in patients with lung cancer and concomitant severe acute respiratory syndrome–coronavirus-2 infection.